New cell therapy for hard-to-treat inflammatory bowel disease
Part of Digestive system clinical trials.
This trial tests a new cell therapy called CNK-UT009 for people with inflammatory bowel disease (like Crohn's or ulcerative colitis) that has been hard to treat. It may reduce inflammation and help you feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate to severe inflammatory bowel disease (Crohn's disease or ulcerative colitis).
- Your condition has not improved with at least two types of biologics or small molecule drugs, or you've had two or more surgeries that have not helped.
- You are not pregnant and are willing to use birth control if you can get pregnant.
- You do not have active infections, cancer, or a recent serious infection (within the last two weeks).
- You have not had surgery or a live vaccine recently and are not planning surgery in the next three months.
- Your organ function (like liver and kidneys) is good enough for the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This early-phase trial is testing a patient-specific immune cell therapy (called CAR-T) for people with active ulcerative colitis or Crohn's disease. The therapy targets two proteins on immune cells to help calm the inflammation in the gut.
This trial tests a new treatment using modified immune cells (CAR-T cells) to reduce inflammation in people with moderate to severe inflammatory bowel disease (IBD) that hasn't improved with other advanced treatments.
This trial tests a new treatment using your own immune cells (called CAR-T cells) to calm down the immune attack that causes ulcerative colitis. It is for people with moderate to severe colitis who have not gotten better with standard medicines.
This trial tests a new cell therapy called CNK-UT for people with severe graft-versus-host disease (aGVHD) that hasn't improved with steroid treatment after a stem cell transplant. The goal is to see if it can help control the immune reaction.
This trial tests an experimental cell therapy called ATORM-C for people with Crohn's disease who haven't gotten better with standard treatments. The goal is to see if this new treatment can help heal the intestinal ulcers that cause symptoms.
Hear when a new Inflamatory Bowel Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.